Dr. Mihaela Ringheanu, MD
Pediatric Gastroenterology (Pediatric Gastroenterology Physician)
512 Victoria Ln Ste 14
Harlingen, TX 78550
Who else practices at this address →
Cameron County is a federal mental health shortage area; it also includes primary care (42% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2005
Licensed in Texas since 2003, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Gastroenterology Physician primary
TX license L7536 (first issued 2003; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 6 companies reported 8 payments worth $361 in total to this clinician.
| Food and Beverage | $361 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $22,478 in research payments for these studies, mostly to the institutions running them.
- Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
Ardelyx, Inc. · Completed · NCT05643534 - An open-label long-term safety study of tenapanor for the treatment of irritable bowel syndrome with constipation (ibs-c) in pediatric patients 6 to less than 18 years old
Ardelyx, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.